Protocol Ledger

NCT07284459 · Phase II · RECRUITING

Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis

Interventional Phase II clinical trial protocol NCT07284459 sponsored by Contineum Therapeutics in Respiratory and Pulmonary, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-01-08 Enrollment: 324 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07284459
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)324 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07284459
Protocol FieldVerified Registry Value
NCT IdentifierNCT07284459
Consolidated Lead SponsorContineum Therapeutics
Therapeutic Condition CohortRespiratory and Pulmonary
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment324 participants (ESTIMATED)
Registered Start Date2026-01-08
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07284459
Hospital Research SiteLocationSite Profile
Royal Prince Alfred HospitalCamperdown, AustraliaOpen Hospital Dossier ->
Westmead HospitalWestmead, AustraliaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Respiratory and Pulmonary Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI